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ABSTRACT
Cancer cells release extracellular vesicles (EVs) that contain functional biomolecules such as RNA
and proteins. EVs are transferred to recipient cancer cells and can promote tumour progression
and therapy resistance. Through RNAi screening, we identified a novel EV uptake mechanism
involving a triple interaction between the chemokine receptor CCR8 on the cells, glycans exposed
on EVs and the soluble ligand CCL18. This ligand acts as bridging molecule, connecting EVs to
cancer cells. We show that glioblastoma EVs promote cell proliferation and resistance to the
alkylating agent temozolomide (TMZ). Using in vitro and in vivo stem-like glioblastoma models,
we demonstrate that EV-induced phenotypes are neutralised by a small molecule CCR8 inhibitor,
R243. Interference with chemokine receptors may offer therapeutic opportunities against EV-
mediated cross-talk in glioblastoma.
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Introduction
Extracellular vesicles (EVs), including exosomes and shed
microvesicles, aremembranous vesicles released bymost, if
not all, cell types. EVs contain active molecules such as
proteins, lipids and nucleic acids, that can exert biological
functions once taken up by recipient cells. EV-mediated
communication is considered to be of particular impor-
tance in tumour progression and therapy resistance. For
several cancer types, it was demonstrated that migratory
and metastatic potential can be phenocopied from one cell
to another by EVs [1–6], and that tumour growth is
enhanced by EVs inmany cancer types, including glioblas-
toma (GBM) [7–10]. EVs are involved in many aspects of
the communication between tumours and their microen-
vironment, such as cell migration and homing, EV-
mediated propagation of GBM heterogeneity and MGMT
promotor methylation status-dependent TMZ resistance
[11–14]. Tumour EVs also exert a protective effect against
several chemotherapeutic agents by delivering a variety of
resistance-inducing molecules such as P-glycoprotein
(P-gp), TrpC5 and non-coding RNAs [15–19].
Despite a possible therapeutic potential of blocking
EV uptake in cancer, this approach is not extensively
exploited owing to the scarce knowledge of EV
uptake mechanisms. EV uptake is considered to
depend on the EV donor and recipient cell type,
their physiological state, and the presence or absence
of interfering molecules in the extracellular microen-
vironment [20–22]. Although direct fusion of EVs
and plasma membranes has been reported for mela-
noma cells [23], multiple studies point to interactions
involving endocytic pathways. EV uptake is inhibited
at 4°C, indicating an active, energy-dependent
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process [24–26]. Proteinase K treatment of either
recipient cells or EVs strongly reduces EV uptake in
several cell types, implying a role of membrane pro-
teins in the internalisation process [26–28]. Co-loca-
lisation studies and assays employing pathway-
specific inhibitors revealed involvement of both cla-
thrin-dependent and clathrin-independent endocyto-
sis, including caveolin-mediated endocytosis,
macropinocytosis and phagocytosis [22]. These
observations seem compatible with receptor-mediated
EV uptake mechanisms, similar as for many envel-
oped viruses [29,30]. To date only few specific cellu-
lar receptors for EVs have been proposed. In an early
study, Tim1 and Tim2 receptors were proposed to
bind phosphatidylserine exposed on EV membranes
of pre-B cells overexpressing these receptors [31].
Integrins have also been shown to act as EV receptors
by binding lysophosphatidic acid from the EV surface
[32]. Furthermore, heparan sulphate proteoglycans
(HSPGs) on the plasma membrane were reported to
function as EV receptors, in a mechanism in which
fibronectin acts as a bridging molecule that interacts
with both cellular and exosomal HSPGs [33,34].
GBM is the most common primary malignant tumour
of the central nervous system in adults and known to
release large amounts of EVs [10,35,36]. Affected patients
have an extremely poor prognosiswith amedian survival of
only 15 months following treatment [37]. Standard of care
currently consists of tumour resection combined with
radiotherapy and concomitant and adjuvant chemotherapy
with the alkylating agent temozolomide (TMZ). Although
tumours may initially respond to this regimen, recurrences
are inevitable and occur even while patients are still receiv-
ing adjuvant TMZ [38]. Here, we show that GBM EVs are
inducers of cell proliferation and are capable of triggering
TMZ resistance in recipient GBM cells. Using RNAi
screening, we identified the chemokine (C-C motif) recep-
tor 8 (CCR8) as a receptor for EVs. CCR8 is known to be
expressed by T-helper 2 lymphocytes, natural killer cells,
and monocytes. In the central nervous system (CNS),
CCR8 expression is associated with phagocytic macro-
phages and activated microglial cells [39]. We demonstrate
that CCR8 is also expressed on tumour cells and this CCR8
allows binding and entry of EVs via interaction of EV-
bound glycans with the chemokine (C-C motif) ligand 18
(CCL18).
Materials and methods
Animal models
Animal experiments were performed in accordance
with the European Community Council Directive
2010/63/EU. The experimental protocol was validated
and approved by the local committee on animal experi-
mentation of the VU University medical centre or The
Netherlands Cancer Institute. Athymic Nude-Fox1nu
mice were purchased from Harlan/Envigo (Horst, The
Netherlands). They were kept under filter top condi-
tions and received food and water ad libitum.
Antibodies and chemicals
MC148 was purchased from B-Bridge international and
was dissolved in PBS. R243 was custom synthesised by
MercaChem (Nijmegen, The Netherlands) and was dis-
solved in dimethyl-sulphoxide (DMSO). Temozolomide
(dissolved in DMSO), 4′,6-diamidino-2-phenylindole
(DAPI), Dynasore, heparin, heparinase III, Dynasore and
PKH67 were obtained from Sigma. BrdU was from Life
Technologies, and recombinant CCL18 and human
Epidermal Growth Factor (hEGF) were from R&D. Basic-
Fibroblast Growth Factor (b-FGF) was purchased from
PeproTech. The antibodies used in thisworkwere obtained
from the following manufacturers: mouse anti-CD63
(Clone NKI/C3) from Fisher Scientific. Mouse anti-Alix
and mouse anti-β-Actin were purchased from Santa Cruz.
Mouse anti-Cre and gold-conjugated rabbit anti-goat were
from Sigma. Rabbit anti-BrdU fromRockland. Rabbit anti-
CCR8 and rabbit anti-GFP fromAbcam. Goat anti-CCL18
from Origene. Rabbit anti phospho-ERK (Phospho-p44/
42 MAPK (Erk1/2) (Thr202/Tyr204)) from Cell Signaling.
HRP-conjugated goat anti-mouse, HRP-conjugated goat
anti-rabbit and HRP-conjugated rabbit anti-goat used as
secondary antibodies in Western blots were from Dako.
IRDYE 800CW mouse anti-rabbit and IRDYE® 680RD
goat anti-mouse also employed for Western blot were
from Li-Cor. Alexa Fluor 405 and goat anti-rabbit Alexa
Fluor 594 from Life Technologies. Protein A-gold (pur-
chased from Cell Microscopy Core, University Medical
Center Utrecht), goat-anti-biotin-Gold (Aureon). Phage
display antibodies (kindly provided by Van Kuppevelt,
Nijmegen) to detect three types of glycosaminoglycans:
VSV-tagged anti-heparan sulphate (HS4E4), VSV-tagged
anti-chondroitin sulphate (1O3H10) andVSV-tagged anti-
dermatan sulphate (GD3A12).
Cell culture, EV isolation and PKH67 staining
HEK-293T, U87 and U251 cells were cultured in
DMEM (Sigma) supplemented with 10% FBS and
0.5 mg/mL Penicillin/Streptomycin (both from
Gibco). GBM8 cells were cultured in Neurobasal-A
medium supplemented with GlutaMax, B27, N2 (all
from Gibco), 2 µg/mL heparin, 20 ng/mL hEGF and
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20 ng/mL basic-FGF. All cells were maintained at 37°
C/5% carbon dioxide.
For EV isolation, exponentially growing cells were
cultured in EV-depleted medium, for 48 h in T175
culture flasks. GBM8 medium does not contain any
source of exogenous EVs and is therefore considered
as EV-free medium. Supernatant, containing secreted
EVs, was collected and subjected to differential centri-
fugation as described previously [40]. Briefly, condi-
tioned medium was cleared of cells, cellular debris and
larger vesicles by spinning at 500 g for 10 min, 2000 g
for 15 min and 10,000 g for 30 min, each step twice.
Finally, EVs were pelleted by centrifugation in a
Beckman Coulter L-90K ultracentrifuge at 70,000 g
for 1 h, washed with 1x cold PBS and pelleted again
at 70,000 g for 1 h. The resulting pellet was resus-
pended in PBS, and EV concentration was estimated
by determining total protein content of the samples by
BCA Assay (Bio-Rad). When indicated, EV isolates
were stained with the lipid dye PKH67 following man-
ufacturer’s instructions and washed extensively with
PBS before re-pelleting at 70,000 g for 1 h.
EV uptake analysis
For EV uptake experiments, subconfluent cell cultures
were incubated with 10 ng/µL of PKH67-labelled EVs
(if not stated otherwise). When indicated, cells or EVs
were treated with recombinant CCL18, anti-CCL18
neutralising antibody, heparin, MC148 or R243 for
1 h before EV addition. After overnight incubation
with labelled EVs, cells were washed with PBS before
fluorescence analysis. PKH67+ cells were either directly
quantified in a Leica DM6000 microscope or analysed
by flow cytometry. As GBM8 medium contains
heparin, GBM8 uptake experiments were conducted
in heparin-reduced medium (0.2 µg/mL).
Western blot analysis
For Western blot analysis on p-ERK, cells 5 × 105
cells were seeded in 24-well plates and isolated EVs
(or PBS in the control wells) were added at a final
concentration of 100 ng/µL at the moment of seeding
and once more 18 h later. At 12 h after second EV
addition, the cells were harvested, washed with PBS
and lysed in RIPA buffer (150 mM NaCl, 50 mM
Tris-HCl (pH 8.0), 1% NP-40, 0.5% deoxycholate,
0.1% SDS) supplemented with Protease Inhibitor
Cocktail (Roche Applied Sciences). For Alix, CD63,
CCL18 or CD9 analysis, 40 µg of EVs were lysed in
RIPA buffer supplemented with protease inhibitor
cocktail. After lysis, cell or EV samples, or
supernatant of the last centrifugation step (negative
control) were loaded in SDS-PAGE gels using
NuPAGE® Novex 4–12% Bis-Tris 1.0 mm gel (Life
Technologies) and the NuPAGE® system from Life
Technologies and were transferred onto 0.45 µm
pore-Immobilon-P PVDF Membrane (Millipore).
After blotting, membranes were blocked for 30 min
in 5% milk (Campina) for CD9, CCL18, Alix and
CD63 analyses and in Rockland Blocking Buffer
(Rockland) for phospho-ERK and β-Actin and incu-
bated overnight with primary antibodies (diluted in
blocking buffer) at 4°C. After three washes with Tris-
Buffered Saline + 0.1% Tween (TBS-T), membranes
were incubated with secondary antibodies (diluted in
blocking buffer) for 1.5 h and washed again three
times with TBS-T before being developed using
Amersham ECL Plus Western Blotting Detection
System (GE Healthcare) (CD9, CCL-18, Alix and
CD63) or scanned in a LI-COR Odyssey scanner
(Biosciences) according to the manufacturers’
instructions (phospho-ERK and β-actin).
Transmission electron microscopy
GBM8 EVs were diluted 1:1 with PBS and coated for a
minimum of 10 min on Formfar coated copper grids
(Electron Microscopy Sciences (EMS)). For the analysis
of size distribution, grids were washed five times after
coating, fixed in 1% glutaraldehyde (EMS) and incu-
bated in 0.5% uranyl acetate (SPI Supplies)/2% methyl
cellulose (SIGMA). A total of nine images (three
images per grid from three separate grids) were
acquired using a transmission electron microscope
(Philips CM100 Bio Twin), connected to a CCD cam-
era (Olympus, Morada G2) and analysed in iTEM
version 5.2 software. Diameters of all EVs found on
these images were measured in iTEM, resulting in a
total of 944 measurements. For immuno-gold stainings,
grids were coated with EVs 1:1 diluted in PBS, washed
five times with PBS supplemented with 1% BSA (PBA),
blocked for 5 min in PBA and 10 min in a commercial
blocking reagent (Aureon) or 10% rabbit serum
(obtained from the Animal facility VU University med-
ical centre). After a minimum of 30 min incubation
with primary antibodies, grids were washed again five
times with PBA before incubation for 20 min with
secondary reagents. Lastly, grids were washed, fixed
in 1% glutaraldehyde and incubated in 0.5% uranyl
acetate/2% methyl cellulose before imaging. Image
acquisition was performed using a transmission elec-
tron microscope connected to a CCD camera and
iTEM software.
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EV interaction analysis
For EV interaction experiments, subconfluent cultures
were incubated with 10 ng/µL of PKH67-labelled EVs
(if not stated otherwise) for 18 h. Although it is firmly
established that uptake of EVs is rapid, and becomes
saturated at 2–3 after incubation, we have incubated
overnight (18 h), because we were not only interested in
EV binding, but also in subsequent processes such as
internalisation, accumulation and cellular distribution
where interference could potentially prevent EV function.
When indicated, cells or EVs were treated with recombi-
nant CCL18, anti-CCL18 neutralising antibody, rCCL1,
rCCL17, heparin (25 µg/mL), heparinase III, MC148 or
R243 (20 µM unless indicated otherwise) for 1 h before
EV addition, except for heparinase III, treatment (2 miU
every 2 h for 6 h at 37°C). After overnight incubation
with labelled EVs, cells were washed with PBS before
fluorescence analysis. PKH67+ cells were either directly
quantified in a Leica DM6000 microscope or analysed by
flow cytometry. As GBM8 medium contains heparin,
GBM8 uptake experiments were conducted in heparin-
reduced medium (0.2 µg/mL).
siRNA validation transfection
For siRNA screening validation of the Top-8 EV uptake-
inhibitingGPCRs, new siRNAs against themwere obtained
from another manufacturer (Qiagen FlexiTube siRNAS:
PTGIR_1: SI00019250, C5R1_1: SI00027412, TRAR3_1
(TAAR9): SI00159208, ADORA2A_1: SI00013874,
MRGX2_1: SI00147994, CXCL3_1: SI00032662, CCR8_7:
SI03027843, GPR172B_1: SI00120295). siRNAs were
transfected in HEK-293T cells with Lipofectamine 2000
following manufacturer’s instructions. Efficient mRNA
knock-down of target genes was verified by quantitative
real-time PCR (data not shown). siRNA screening results
were also validated in GBM8 cells by electroporation of
Qiagen’s siRNAswith amicroporatorMP-100 (Digital Bio,
Seoul, South Korea) following manufacturer’s instructions
with a single pulse of 1400 V for 40 ms. At 48 h after
transfection, HEK-293T and GBM8 cells were incubated
overnight with 20 ng/µL of PKH67-labelled EVs, washed
twice with PBS and subjected to fluorescent EV uptake
analysis. As a control for EV uptake inhibition in GBM8
cells, siRNA control cells were treated with Dynasore
(80 µM)– aDynamin2 inhibitor know to impair EVuptake
[22] – for 30 min before incubation with labelled EVs.
RNA isolation and RT-PCR
A total of 5 × 105 cells or 40 µg of EVs were lysed in
lysis/binding buffer, and RNA was isolated using the
total RNA extraction protocol from the MirVana kit
(Ambion) following manufacturer’s indications. After
isolation, RNA integrity and concentration were deter-
mined on an Agilent 2100 Bioanalyzer using Agilent
Small RNA kit (Agilent Technologies, Germany), con-
centration of the samples was adjusted to the minimum
concentration of the samples analysed and cDNA was
synthesised using Omniscript RT kit for RNA samples
above 50 ng or with Sensiscript RT kit when RT reac-
tions contained less than 50 ng (both kits were from
Qiagen) following manufacturer’s instructions.
Small RNA sequencing and data analysis
The RNA quality from GBM cell lines and matched EVs
was analysed on Agilent 2100 Bioanalyzer using Agilent
Small RNA kit (Agilent Technologies, Germany).
Maximum sample input (6 µL) was prepared for sequen-
cing using the Illumina TruSeq small RNA Preparation
Kit according to the manufacturer (Illumina). RNAseq
was performed on a HiSeq 2500 (Illumina) pair-end 125
nucleotide length read, using equimolar amounts for
each sample. Sequencing reads analysis was performed
by using the sRNAbench analysis package as described
previously [41]. Briefly after adaptor trimming and
unique reads grouping, reads were aligned to the
human genome (UCSC hg19) using the Bowtie 1.1.2.
To provide annotations for RNA elements that mapped
to human genome, several databases were used, includ-
ing miRBase (version 21) for mature and pre-miRNA
sequences and NCBI Reference Sequences (RefSeq
Release 69, 2 January 2015). Apart from the main
sRNAbench programme, a differential expression mod-
ule based on edgeR (Robinson et al., 2010) was used to
generate an expression matrix of all miRNAs detected.
Note that by using edgeR, sRNAbench applies implicitly
TMM normalisation in the detection of differentially
expressed small RNAs, which was reported to be
among the most stable methods [42,43].
Relative cell number quantifications
Relative number of cells in GBM8 spheres was esti-
mated by calculating GBM8 sphere volumes, assuming
the volume of a neurosphere to be proportional to the
number of cells comprising it. When seeded at low
density in round-bottom, cell-repellent 96-well plates
(Greiner Bio-One), GBM8 cells form a single, nearly
perfectly spherical neurosphere. Using a Leica DM
3000B motorised microscope equipped with a Pulnix
JAI RMC-1327GE camera, pictures of individual
spheres were taken. Moreover, the area covered by
the sphere was calculated using ImageJ software.
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Radius of the sphere was calculated as the square root
of the area divided by Pi, and relative sphere volume
was calculated by taking four thirds of Pi multiplied by
the third power of the calculated radius. When stated,
R243 and/or TMZ (20 µM or otherwise indicated con-
centrations) were directly added to the culture medium
immediately after seeding the cells. EVs were added at
a final concentration of 100 ng/µL once 30 min after
drug treatments and again 24 h later. Spheres were
measured between 5 and 7 days after treatments. IC50
value determination for R243 on GBM8 cells, as well as
TMZ/R243 combination studies were performed using
CellTiter-Glo kit (Promega), and GBM-FM relative cell
numbers in Figure 1 (E) were estimated by luciferase
assay (Promega). Both assays were performed following
manufacturer’s recommendations.
Development of Cre and mTmG lines and in vitro
Cre-mT/mG EV transfer studies
The Cre-expressing GBM8 cell line was generated by
lentiviral transduction of the plasmid Puro.Cre empty
vector (Addgene #17,408), followed by puromycin
selection for 1 month. Homogeneity of Cre expression
in GBM8-Cre cells was verified by immunocytochem-
istry. GBM8 mT/mG cells were generated by releasing
the entire (linearised) mT/mG cassette from ROSA26
mT/mG plasmid (Addgene #17,787) by restriction
with AscI, AccI and PmeI (New England Biolabs),
band purification and electroporation with a micro-
porator MP-100 (Digital Bio, Seoul, South Korea)
following manufacturer’s instructions with a single
pulse of 1400 V for 40 ms. After 1 month in culture,
cells still expressing mTomato protein were sorted by
flow cytometry in a FACSARIA instrument (BD
Biosciences). Functionality of the mT/mG cassette
was verified by incubating the lenti Puro.Cre virus
directly on GBM8-mT/mG cells and observing
appearance of mG+ cells 96 h later. For EV transfer
studies, 1 × 104 GBM8-mT/mG cells were seeded in 6-
well plates and Cre-donor EV isolates were added at a
final concentration of 10 and 40 ng/µL. An equivalent
volume of PBS was added as negative control.
Alternatively, a total 104 GBM8-mT/mG and GBM8-
Cre cells were co-cultured at 1/10 and 1/100 ratios of
mT/mG vs Cre cells. As a negative control, GBM8-
mT/mG cells were co-cultured with parental Cre−
cells. After 12 days in culture, wells were inspected
for the presence of spheres with GFP+ cells in a Leica
DM IL microscope equipped with a DFC345 FX cam-
era. Results were expressed as % of GFP+ spheres
relative to the total spheres.
In vivo Cre-mT/mG EV transfer studies
Vesicles were harvested by ultracentrifugation of con-
ditioned medium from Cre-containing GBM8 cells or
from parental cells. For tumour-to-tumour crosstalk,
GBM8-mTmG cells, GBM8-Cre cells and GBM8 par-
ental cells were prepared and concentrated as indicated
above. Shortly before intracranial injection, GBM8-
mTmG were washed once with phosphate buffered
saline (PBS) and concentrated to 1.2 x 105 cells per
µL. Mice were stereotactically injected with 6 × 105
cells in a final volume of 5 µL into the striatum. All
intracranial injections were performed using isoflurane
inhalation anaesthesia (1.5 L O2/min; 2% isoflurane)
and appropriate systemic and topical analgesia.
Coordinates used for intracranial injections were
0.5 mm X, 2 mm Y, −2.5 mm Z from the bregma [1].
Three days after injection of GBM8-mTmG tumour
cells, 10 µL vesicle suspension (15 µg) was injected
into the tumour, using the same coordinates. GBM8-
mTmG cells were injected in the striatum of the left
hemisphere; whereas, GBM8-Cre (n = 6) or GBM8
parental cells (n = 6) were injected in the right hemi-
sphere. Three weeks after tumour injection, mice were
sacrificed and cryosections (8 µm thick) of brains were
prepared. Fluorescence of endogenous mTomato and/
or GFP in the left hemisphere was imaged in DAPI
stained cryosections using a Zeiss Fluorescence
microscope.
GPCR siRNA screening
For the GPCR siRNA screening, HEK-293T cells were
plated in 96-well plates at a density of 5 × 104 cells/mL.
After an overnight incubation, cells were transfected
with a siGENOME Smartpool siRNA library-G
Protein-Coupled Receptors (50 nM, Dharmacon)
using Lipofectamine 2000 as a transfection reagent
following manufacturer’s indications. This library con-
tains siRNAs against 512 individual GPCRs and
GPCR-associated genes. After 48 h, 20 ng/µL of
PKH67-labelled EVs was added to the plates. As con-
trols for EV uptake reduction, every plate was loaded
with a standard curve of labelled EVs (20, 10, 5 and 0
ng/µL) on untransfected cells. After overnight incuba-
tion with stained EVs, plates were washed twice with
PBS, nuclei were stained with DAPI and plates were
scanned in an Acumen eX3 (TTP LabTech, Melbourne,
UK) microplate cytometer. After this overnight incuba-
tion time, the fluorescence signal represents the sum of
multiple EV interactions and processes, including cell-
surface bound EVs and intracellular EVs. Fluorescence
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levels were normalised by mean fluorescence intensity
of all the plates excluding controls and divided by the
number of nuclei determined by DAPI staining.
Flow cytometry
For FACS analysis, cells were washed in PBS, resus-
pended in PBS supplemented with 1% BSA (PBS-BSA)
and analysed with FACSDiva software in a BD Fortessa
instrument. Collected data were processed with
flowJoX software. CCR8 expression analysis was con-
ducted by incubating cells with anti CCR8 antibody for
30 min on ice, washing them three times with PBS-BSA
and incubating them with an Alexa Fluor 405-coupled
secondary antibody for another 30 min. Cells were
analysed after three more washes with PBS-BSA. For
the BrdU incorporation assay, cells were seeded at a
density of 4 × 105 cells/mL and EVs (or PBS in the
control wells) were added at a final concentration of
100 ng/µL at the moment of seeding and once more 18
h later. At 12 h after second EV addition, cells were
incubated for 2 h with BrdU and washed with PBS
prior fixation with 4% paraformaldehyde (PFA) for
15 min. Membranes were permeabilised with 100%
cold methanol and cells were washed with DNAse
buffer (10 mM Tris, 2.5 mM MgCl2, 0.1 mM CaCl2)
and treated with DNAseI diluted in DNAse buffer at
RT for 20 min. Cells were washed in immunocyto-
chemistry (ICC) wash buffer (1x PBS, 0.1% Triton
TX-100, 0.05% Azida, 1% BSA), blocked in wash buffer
containing 10% fetal bovine serum (FBS) for 20 min at
room temperature and incubated overnight with anti-
BrdU primary antibody at 4°C. After three wash steps,
Alexa Fluor 405-coupled secondary antibody was incu-
bated at RT for 2 h. Before analysis by flow cytometry,
samples were washed three times in ICC wash buffer.
CCR8 and CCL18 expression and patient survival
analysis
Expression and Kaplan–Meier analyses were performed
using the R2 online platform (R2.amc.nl). To distin-
guish expression levels of GBM versus normal brain
tissue, MAS5.0 normalised, u133p2 microarray data of
the French Tumour Glioma Dataset (gse16011), con-
taining 276 glioma samples of all histology and 8 con-
trol samples; the Sun Tumour Glioma dataset
(GSE4290) containing 157 tumour samples including
26 astrocytomas, 50 oligodendrogliomas and 81 glio-
blastomas; and the Hegi Tumour Glioblastoma dataset
(GSE7696), containing 80 GBM specimens of patients,
were compared to eight normal samples present in the
French dataset; the Berchtold Normal Brain regions
dataset (GSE11882) containing 176 samples from hip-
pocampus, entorhinal cortex, superior-frontal gyrus,
and postcentral gyrus brain tissues, and the Harris
Normal Brain PFC dataset (GSE13564), containing 44
prefrontal cortex brain tissues [44–46]. Kaplan–Meier
analyses were performed using the French dataset. The
significance of the difference in expression levels of
CCR8 and CCL18 between tumour versus normal
brain tissues was determined using a t-test. The signif-
icance of the Kaplan analyses was tested using a Mann–
Whitney test. For this, the most optimal expression
threshold point was determined.
Immunocytochemistry, immunohistochemistry,
tissue microarray and chemokine array
For immunocytochemistry, attachment of cells to glass
coverslips was induced by adding 10% FBS for 2 h.
Then, coverslips were washed with PBS, fixed with 4%
PFA for 15 min and treated with cold methanol. After a
wash in ICC wash buffer, coverslips were blocked in
ICC wash buffer containing 10% FBS for 20 min at
room temperature and incubated overnight with anti-
Cre or anti-CCR8 primary antibodies at 4°C. After
three wash steps, Alexa Fluor 488-coupled (Cre) or
Alexa Fluor 594-coupled (CCR8) secondary antibodies
were incubated at RT for 2 h. Slides were washed three
times before and after DAPI counterstain and mounted
with Vectashield (Vector Laboratories) on glass slides.
For analysis of GBM8 mT/mG xenografts, brain cryo-
sections (10 µm thick) were fixed in 4% PFA, washed
three times with PBS for 10 min before and after
counterstaining with DAPI and mounted on glass cov-
erslips with Vectashield. Pictures were taken with a
Leica DM6000 microscope and processed with ImageJ
software. GFP Immunohistochemistry
(Abcam; ab 6556; 1:1000) was performed on cryopre-
served tissue slides following standard procedures.
Slides were scanned using Aperio Scanscope and pro-
cessed with ImageScope software (Leica). Tissue micro
array – GL805a (TMA) containing glioblastoma sam-
ples and control tissues was purchased from US
Biomax Inc. After deparaffination and microwave-
induced antigen retrieval (Tris-EDTA pH9.0), TMA’s
were stained with anti-CCR8 antibody (E77, Abcam)
and anti-rabbit/mouse EnVision-HRP (DAKO). For
negative staining, the first antibody was omitted.
CCR8 expression was calculated based on the stained
area (0–4) and staining intensity (0–4), thus resulting
in a maximal value of 16. To detect chemokines
secreted by GBM8 cells, Proteome Profiler™ Human
Chemokine Array Kit (R&D Systems) was used to
detect secreted chemokines in GBM8 conditioned
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medium following manufacturer’s instructions. Briefly,
array membranes were blocked and incubated for 2 h
with conditioned medium collected from cells growing
at 2.5 x 105 cells/mL for 24 h and diluted 1:1 in block-
ing buffer. After washing, membranes were incubated
with a cocktail of biotinylated human chemokine anti-
bodies in blocking buffer at RT for 2 h and then
incubated with horseradish peroxidase (HRP)-conju-
gated streptavidin in blocking buffer overnight at 4°C
following further washes. After three washes, mem-
branes were developed using Chemi Reagent Mix and
visualised on X-ray film (GE healthcare).
Enzyme-linked immunosorbent assay
To detect EV-associated molecules, a fixed concentra-
tion of 5 ng/µL or serial dilutions of isolated EVs were
coated overnight at 4°C in coating buffer (0.2 M
NaHCO3, pH 9.2) on ELISA plates. Plates were washed
twice with TSM buffer (20 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM CaCl2, 2 mM MgCl2) and blocked with
1% BSA in TSM for 1 h at room temperature. Plates
were then incubated with primary antibodies at a fixed
concentration (1 µg/mL) or in serial dilutions (from
4 µg/mL to 62.5 ng/mL) in TSM buffer with 1% BSA
for 1 h at room temperature. After three washes with
TSM buffer, plates were incubated with secondary anti-
bodies at RT for 1 h, washed again three times, and the
reaction was developed, using 3,3′,5,5′-tetramethylben-
zidine (TMB) as a substrate (Sigma Aldrich). Signal
intensities were acquired with a Biotek Synergy HT
microplate reader.
In vivo analysis of R243 and TMZ treatment
Treatment with R243 (1.0 mg/kg, i.p. once daily) or
vehicle (1% DMSO in PBS) was started at day 4 after
tumour injection and continued until day 8. At day 5,
animals were treated once with 10 mg/kg TMZ, i.p., or
vehicle (4% DMSO in PBS). Stocks of R243 (100 µM;
35.7 mg/mL) were prepared in DMSO and stored at
−20°C. Working solutions were prepared freshly before
each administration by diluting R243 stock solution
in PBS.
Bioluminescence imaging
Tumour progression was followed by measuring firefly
luciferase (Fluc) signal by a charge-coupled device
(CCD) camera, using the Xenogen-IVIS Lumina system
under isoflurane anaesthesia. Mice were injected
intraperitoneally with 150 µL D-luciferin (100 mg/kg).
Regions of interest were defined on the head of the
mice. The photon flux (p/s) in these regions was used
as a total measurement of Fluc activity. Photon flux was
normalised to the group means at day 8 (Figure 7(E)).
Disease progression was defined as the time point at
which for two consecutive measurements an increase in
BLI was observed.
Pharmacokinetic studies
WT FVB mice and transgenic Abcg2−/-, Abcb1a/b−/-
and Abcg2; Abcb1a/b−/- FVB mice were used in phar-
macokinetic studies. R243 was administered i.v. at a
dose of 10 mg/kg in a formulation containing 2 mg/mL
R243 in DMSO:Cremophor EL:saline (1:1:8). Blood
and brains were collected 1 h after administration.
Plasma was obtained by centrifugation (5 min, 5000
rpm, 4°C) and brains were weighed and homogenised
using a FastPrep®-24 (MP-Biomedicals, NY, USA) in
1% (w/v) bovine serum albumin in water. R243 was
extracted by liquid–liquid extraction using ethyl acetate
and measured using LC–MS/MS.
In vitro translocation assays
Conventional bidirectional translocation assays were
performed using parental MDCK cells as described
previously [47] R243 was added to either the apical or
basolateral side of a Transwell microporous polycarbo-
nate membrane filters (3.0 µm pore size, 24 mm dia-
meter; Costar Corning, Corning, NY, USA) at a
concentration of 100 nM and translocation over time
was measured using LC–MS/MS. Complete R243
translocation was reached when an equilibrium
between both compartments was established.
Accession numbers
The raw sequencing data are deposited at a public
database. The NCBI SRA accession number for the
small RNA sequencing by Illumina Hi-Seq 2500
reported in this paper is SRP092232. Small RNA sequen-
cing data used in the analysis for Supplementary Figure
9 is presented in Supplementary Table S1 with the list of
human miRNAs detected in GBM8 cells and their
paired EVs. Individual miRNA sequencing reads
mapped to human miRNAs are detected in cells and
their paired EVs. Highlighted in yellow are miRNAs
represented in Supplementary Figure 9. RPM, reads
per million of normalised reads (relative expression).
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Results
GBM EVs induce a proliferative phenotype in
recipient GBM cells
To confirm the pro-tumoural capacity of EVs on GBM
cells we isolated EVs from GBM-conditioned media by
differential ultracentrifugation [40,48]. EVs isolated from
stem-like GBM8 cells (a primary stem-like GBM cell type)
had diameters ranging from 30 to 200 nm (Figure 1(a),
Supplementary Figure 1(a)) and expressed CD63, Alix and
CD9 (Figure 1(b)). EVs isolated from U87 and U251 were
phenotypically similar to GBM8 EVs and also expressed
EV markers (Supplementary Figure 1(b,c)). GBM8 cells
were incubated with isolated and PKH67-labelled GBM8
EVs, resulting in a dotted fluorescent pattern, indicating
efficient EV binding (Figure 1(c)). Similar results were
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indicates p-value ≤0.001 and **** indicates p-value ≤0.0001 as determined by ANOVA.
8 J. BERENGUER ET AL.
obtained for U251 and U87 (Supplementary Figure 1(d)).
The active uptake of EVs was confirmed by the uptake of
PKH67-labelled GBM8-derived EVs after 1-h incubation,
which was efficiently blocked by the addition of dynasore
(Supplementary Figure 1(e)). Using FACS analysis, the
proportion of PKH67+ cells after incubation with labelled
EVs showed a sigmoidal log-linear dose–response relation-
ship with the amount of PKH67-labelled EVs added
(R = 0.9998). Co-incubation of PKH67-labelled EVs with
increasing concentrations of unlabelled EVs resulted in a
dose-dependent reduction in mean fluorescence intensity
(Supplementary Figures 1(f,g)) [39,40]. These results
prompted us to quantify EV-mediated proliferation. We
incubated GBM8 cells with fresh (EV-free) medium or
with medium supplemented with isolated GBM EVs,
resulting in enlarged stem-like GBM8 neurospheres and
an increase in total cell number in cells supplemented with
exogenous EVs (Figure 1(d)). The EV-mediated induction
of proliferation was significant and dose-dependent,
increasing GBM8 stem-like cell numbers by 2.4-fold
when cells were incubated with 250 ng/µL of isolated
EVs (Figure 1(e)). Addition of exogenous EVs resulted in
a 1.5-fold increase in 5-bromo-2′-deoxyuridine (BrdU)
incorporation, indicating that the observed increase in
cell number is, at least partially, due to an enhanced pro-
liferation rate (Figure 1(f)). EV exposure also induced
activation of the MAPK-ERK pathway, as evidenced by
an increase in phospho-ERK levels (Figure 1(g)). Because
MAPK-ERK activation is also implicated in TMZ resis-
tance in GBM cells [49], we validated the effects of TMZ
treatment in the presence of EVs. After determining the
IC50 value of TMZ on GBM8 cells (~20 µM,
Supplementary Figure 2), we treated cells with 20 µM
TMZ in the presence or absence of 100 ng/µL of purified
EVs. As shown in Figure 1(h), addition of exogenous EVs
indeed resulted in strong protection against TMZ-
mediated cell kill, although a partial contribution of a
concomitant induction of cellular proliferation is not
excluded.
To determine whether functional transfer by EVs
occurs at physiologically relevant levels, we used a colour
switch system based on EV-mediated Cre recombinase
mRNA transfer [1]. Reporter mT/mG cells contain a
floxed copy of membrane-tagged Tomato (mT). Upon
Cre-mediated recombination the mT sequence is excised
allowing expression of a membrane-tagged GFP (mG)
located immediately downstream, resulting in a colour
switch from mT+ (red) to mG+ (green) (Supplementary
Figure 3(a)). Cre protein expression in stably transduced
EV donor cells was confirmed by immunocytochemistry
(Supplementary Figure 3(b)), and functionality of the
reporter cells was verified by incubating cells with Cre-
expressing lentivirus (Supplementary figure 3(c)). RT-PCR
analysis revealed presence of Cre mRNA in EVs isolated
from these donor cells (Supplementary Figure 3(d)).
Addition of purified Cre+ EVs isolated from Cre donor
cells induced patches of mG+ cells in recipient GBM8-mT/
mG stem-like neurospheres (Supplementary Figure 3(e)).
In order to determine whether transfer of biologically
functional molecules was also achieved by natural secre-
tion of EVs from donor cells, we conducted co-culture
experiments, with no exogenous addition of EVs, resulting
again in the appearance of clusters of mG+ cells and thus
confirming efficient Cre transfer in a more physiological
setting (Supplementary Figure 3(f)).
Altogether these results indicate that GBM EVs can
transfer cargo, and that EV interaction results in acti-
vation of the MAPK-ERK pathway, induces prolifera-
tion, and that EVs can reverse TMZ sensitivity.
CCR8 acts as an EV receptor
To identify cellular receptors involved in EV uptake,
we performed siRNA screening using PKH67-
labelled EV uptake by HEK-293T cells as readout.
HEK-293T cells were selected because the conditions
for siRNA screening of these cells were considered
more favourable as compared to primary stem-like
GBM neurospheres. We selected a siRNA library
against G-protein coupled receptors (GPCRs)
because of the highly versatile roles of GPCRs in
many cellular processes, including viral entry, and
because many GPCRs are potentially druggable.
After testing that GBM EVs are efficiently taken up
by HEK-293T cells and that EV uptake is dose-
dependent (Supplementary Figure 4(a,b)), we trans-
fected the GPCR siRNA library. At 48 h after trans-
fection, cells were incubated overnight with labelled
EVs and fluorescent cells were recorded
(Supplementary Figure 4(c)). A total of 65 of 512
siRNAs caused a reduction in fluorescent signal
stronger than 30%. From these, we selected the top-
8 for further validation with an independent set of
siRNAs (Figure 2(a)). CCR8 inhibition caused a
strong and consistent reduction in EV uptake in
both HEK-293T and GBM8 cells and therefore was
selected for further studies (Figure 2(b) and
Supplementary Figure 4(d)).
CCR8 is a beta chemokine receptor with a known
role in induction of chemotaxis in Th2 cells via its two
ligands CCL1 and CCL18 [50], and functions as a co-
receptor for enveloped viruses including HIV [51,52].
The CCR8 axis has been found to be activated in
urothelial and renal carcinomas resulting in immune
response impairment, and it is responsible for apopto-
sis inhibition in lymphoma [53,54]. Furthermore,
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CCR8 function in melanoma cells is essential for the
entry of metastatic cells into lymph nodes [55]. We
show the relevance of CCR8 on EV uptake in GBM8
cells by the dose-dependent reduction of uptake in the
presence of increasing concentrations of MC148, a
highly selective virus-encoded CCR8 antagonist [56]
(Figure 2(c)). According to the CCR8 expression levels,
GBM8 cells can be divided into two populations. One
population expresses undetectable levels of CCR8
(CCR8− cells), whereas the other population shows
significant CCR8 immunoreactivity (CCR8+ cells)
(Figure 2(d) and Supplementary Figure 4(e)). In several
independent experiments, we have observed variable
proportions of CCR8+ GBM cells, ranging from 20%
to 80%. Interestingly, when we combined labelled EV
uptake with CCR8 immunostaining, we observed that a
significantly larger proportion of CCR8+ cells take up
PKH67-labelled EVs than do CCR8− cells (Figure 2(e)),
strongly suggesting that CCR8 participates in the
uptake process.
CCR8 inhibition neutralises EV-induced phenotypes
in vitro
R243 is a small molecule which functionally inhibits CCR8
both in vivo and in vitro [57]. We therefore synthesised a
batch of R243 to test its effect on inhibiting EV uptake
(chemical synthesis scheme in Supplementary Figure 5(a)).
As expected, R243 treatment strongly impaired EV uptake
(Figure 3(a,b)). CCR8 inhibition by R243 or MC148
occurred at early time points (3 h), suggesting a role in
early steps of EV uptake (Supplementary Figure 5(b)). We
then tested whether R243 could counteract EV-induced
phenotypes on recipient GBM cells. After determining the
IC50 value of R243 on GBM8 cells (44 µM, Supplementary
Figure 5(c)), we pre-treatedGBM8 cells with R243 (20 µM)
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for 30 min, incubated the cells with isolated EVs and
measured the total number of GBM cells after 96 h. As
shown in Figure 3(c), R243 alone had no measurable effect
on GBM cell growth; whereas, R243 pre-treatment was
able to completely block EV-induced GBM cell growth.
Next, we studied whether addition of R243 would improve
the effect of TMZ treatment. Combined treatment of GBM
cells resulted in enhanced potency of TMZ, with combina-
tion indexes [58] down to 0.8 (Figure 3(d)).We studied the
effects of R243 on GBM cells treated with TMZ in the
presence of isolated EVs. Interestingly, although EV sup-
plementation alone restored cell numbers after TMZ treat-
ment, R243 treatment partially prevented this EV-induced
resistance to TMZ (Figure 3(e)). As shown in
Supplementary Figure 5(d–h), R243 reduced EV uptake
by three different GBM lines tested, although with variable
potency. We also observed a significant effect of the drug
on A375 cells (malignant melanoma), but not on A549
cells (lung carcinoma). These results suggest that CCR8
may also function as an EV receptor on certain non-GBM
cell types.
CCR8 and CCL18 expression levels are increased in
GBM and are indicators of poor prognosis
To determine whether CCR8 expression has implications
in tumour progression in GBM patients, we performed
immunostaining against CCR8 on a tissue microarray
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(TMA) from glioma samples of patients with different
glioma grades, including grade IV GBM. Tumour cells
exhibited different immunoreactivity patterns which we
scored depending on the intensity of the staining.
Blinded classification of array specimens revealed a signif-
icant increase in CCR8 expression in grade IV GBM as
compared to normal (non-tumoural) brain tissues
(Figure 4(a,b) and Supplementary Figure 6). We also per-
formed metadata analysis on publicly available microarray
data using the R2 Analysis and Visualisation Platform
(http://r2.amc.nl). Results showed increased mRNA levels
of both CCR8 and its natural ligand CCL18 in GBM as
compared to normal brain samples (Figure 4(c,d)).
Moreover, survival analyses indicate that both CCR8 and
CCL18 are indicators of poor prognosis in GBM patients
(Figure 4(e,f)).
CCL18 acts as a bridging molecule between gags
on EVs and cellular CCR8
We performed EV uptake analyses in the presence of
CCL1 and CCL18, the two known ligands of CCR8, as
well as with neutralising antibodies directed against
these chemokines. Recombinant CCL18 addition signif-
icantly increased EV uptake, and the CCL18 neutralising
antibody decreased uptake (Figure 5(a,b)), whereas addi-
tion of recombinant CCL17 had no effect, and the
addition of rCCL1 even resulted in a small, but signifi-
cant, reduction of EV uptake at the highest dose
(Supplementary Figure 7(a,b)). These results suggest
that CCL18 plays a mediating role in the EV uptake
via CCR8. Chemokine arrays were used to determine
that GBM8 cells secrete many chemokines, including
CCL18 (Supplementary Figure 7(c)). Given that EV
membranes are highly glycosylated [59,60], and that
chemokines bind with high affinity to glycans [61,62],
we considered the possibility that CCL18 could be acting
as a bridging molecule between glycans on the EV
membrane and the cellular receptor CCR8. We incu-
bated isolated EVs with recombinant CCL18 overnight,
washed the EVs with PBS and purified them again.
Western blot analysis revealed that CCL18 can be
detected in the EV pellet but not in the supernatant,
confirming effective binding of CCL18 to EVs
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(Supplementary Figure 7(d)). We incubated ELISA
plates with isolated GBM8 EVs and confirmed proper
vesicle coating by detection with the marker CD63
(Figure 5(c) and Supplementary Figure 7(e)). This sys-
tem also allowed us to detect endogenous CCL18, but
not CCL1 on GBM8 EVs (Figure 5(d) and
Supplementary Figure 7f, g). To further confirm
CCL18 presence on GBM8 EVs, we performed immu-
nogold EM on isolated EVs, observing exosome-like
vesicles with strong immunoreactivity against CCL18
and CD63 (Figure 5e, f).
Next, we validated the presence of glycans on GBM
EV membranes. As shown in Figure 6(a–c), GBM8 EVs
are rich in heparan sulphate, chondroitin sulphate and
dermatan sulphate, the main glycosaminoglycans
(GAGs) produced by eukaryotic cells [63–65].
Chemokine–glycan interactions occur mainly by elec-
trostatic forces. Heparin is a soluble and highly
sulphated GAG, capable of displacing chemokine–gly-
can interactions owing to its high negative charge den-
sity [61,62,66]. Furthermore, heparin has been shown
to efficiently bind and capture EVs [67]. We reasoned
a
**
***
b
0.5
1
1.5
0
A
bs
or
ba
nc
e 
CCL18
d
Log [EV] (ng/µl)
-0.5 0.0 0.5 1.0 1.5
c
1
2
3
0
-0.5 0.0 0.5 1.0 1.5
A
bs
or
ba
nc
e
CD63
Log [EV] (ng/µl)
Ab CTRLAb CTRLCCL18 CD63
e f
*
n.s.
0 10 100
80
100
120
140
160
CCL18 (ng/μl)
%
E
V
u
pt
ak
e
0 1 10
0
20
40
60
80
100
120
anti-CCL18 (ng/μl)
%
E
V
u
pt
ak
e
Anti-CCL18 (ng/µl)CL18 (ng/µl)
Figure 5. CCL18 enhances EV uptake. (a) EV uptake analysis on GBM8 cells incubated with recombinant CCL18 prior PKH67-EV
addition. (b) EV uptake analysis on EVs pre-incubated with CCL18 neutralising antibody. * indicates p-value ≤0.05, ** indicates
p-value ≤0.01, *** indicates p-value ≤0.001 as determined by ANOVA. (c,d) ELISA results on plates coated with dilutions of isolated
EVs and incubated with anti-CD63 (c) or anti-CCL18 (d). Both incubations displayed dose-dependent signal. (e) Immunogold EM
pictures showing GBM EVs with strong reactivity against endogenous CCL18. (f) Positive control: Immunogold staining against the
exosomal marker CD63. Ab control: No primary antibody (Scale bars: 25 nm).
JOURNAL OF EXTRACELLULAR VESICLES 13
that if CCL18 binding to EVs is essential for cellular
uptake, pretreatment of EVs with heparin should cause
CCL18 to be displaced from the EV membrane conse-
quently, resulting in diminished uptake. Indeed,
heparin pretreatment reduced EV uptake by 80%
(Figure 6(d)). This result is in agreement with a pre-
vious report from Paggetti and colleagues in which
heparin treatment of chronic lymphoid leukaemia-
derived EVs caused a strong reduction in EV uptake
[28]. To further demonstrate the involvement of GAGs
in the uptake process, we treated purified EVs with
Heparinase III (H’se III), which cleaves 1–4 linkages
between hexosamine and glucuronic acid residues in
heparan sulphate molecules. H’se III treatment reduced
EV uptake by approximately 40%, confirming that
glycans exposed on the EV membrane facilitate EV
uptake (Figure 6(e)). Collectively, these results reveal
an EV uptake model in which CCL18 acts as a ‘con-
nectokine’ between glycans decorated on the EV mem-
brane and the cellular receptor CCR8 (Figure 6(f)).
Pharmacological inhibition of CCR8 delays tumour
growth after TMZ treatment
A common problem in the development of drugs for
GBM treatment is the blood–brain barrier (BBB).
Therefore, we first verified that R243 is capable of
reaching the brain. Specific transporter proteins pre-
sent on the BBB are known for their role in blocking
drug delivery to the brain [68]. By using wildtype
mice, and transgenic mice deficient for the transpor-
ters Abcg2 and Abcb1a/b [68,69], we show that these
drug transporters have no meaningful impact on the
brain penetration of R243 (Figure 7(a–c)).
Intriguingly, the brain-to-plasma ratio of R243 was
35 in wildtype mice, unusually high, pointing to a
remarkable accumulation of R243 into the brain
(Figure 7(d)). Next, to test the effects of R243 on
GBM in vivo, we employed a version of GBM8 cells
(GBM8-FM) stably expressing mCherry protein and
firefly luciferase, which allows monitoring of tumour
growth by bioluminescence imaging. Subsequently,
we tested with the Cre-mT/mG EV reporter system
the ability of in vivo transfer of EV cargo. We ortho-
topically injected GBM8-mT/mG recipient cells in the
brain of nude mice (n = 6). Three days after implan-
tation of the recipient reporter cells, we injected EVs
isolated from Cre+ (n = 3) or Cre− (n = 3) donor cells
in the brains of these mice. Two weeks later the mice
were sacrificed and the brains were resected, sliced
and analysed by fluorescent microscopy. The tumour
tissues consisted mostly of red mT+ cells, but tumour
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areas with abundant mG+ cells were also observed in
three out of three mice injected with Cre+ EVs, in
contrast to the brains of the three mice injected with
Cre− control EVs, where no mG+ cells were detected
(Supplementary Figure 8(a)). Next, we investigated
whether physiological levels of locally produced Cre+
EVs – by co-injection of GBM8-Cre donor cells with
GBM8-mT/mG recipient cells – can also result in
functional transfer of Cre. Hence, we co-injected
mice with mT/mG recipient cells in one hemisphere,
and Cre+ or Cre− donor cells in the opposite hemi-
sphere of the brain in order to minimise the risk of
cell contact-dependent Cre transfer. Again, the brains
of three out of three mice co-injected with Cre+ cells
displayed patches of mG+ cells in mT/mG tumours, in
contrast to mice co-injected with Cre− GBM cells
which resulted only in mT+ cells (Supplementary
Figure 8(b)). The presence of mG+ cells was further
validated by anti-GFP immunostaining of mouse
brain slices (Supplementary Figure 8(c)). These results
demonstrate that EVs can indeed provide functional
transfer of cargo-like RNA molecules, or proteins in
orthotopic brain tumours, albeit that the efficiency of
the Cre–mT/mG reporter system under these condi-
tions is relatively low. Next, we tested if we could
inhibit the EV mediated protumoural effects in vivo,
by the administration of the CCR8 inhibitor R243. As
shown in Figure 7(e,f), R243 administration did show
a trend in reducing primary GBM stem-like xenograft
growth in nude mice (n = 6), although no significant
effects were reached. However, when we administered
R243 before and after TMZ treatment in nude mice
(n = 6), the effect of TMZ was significantly enhanced,
and tumour recurrence was significantly delayed as
compared to TMZ treatment in the absence of R243
(Figure 7(e,f)). In conclusion, under these conditions,
R243 only showed a minor non-significant effect
when administered alone, and perhaps repeated dos-
ing and/or earlier treatment would be more beneficial.
However, administration of R243 in combination with
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TMZ did demonstrate a significant delay of recur-
rence after TMZ treatment and warrants further pre-
clinical testing (Figure 7(g)).
Discussion
We present three main findings related to EV uptake by
GBM cells: (i) GBM EVs can be transferred between
GBM cells in vitro and in vivo, stimulating GBM cell
growth and protecting against TMZ; (ii) CCR8 acts as
an EV receptor on GBM cells and binds to CCL18, which
acts as a bridging molecule to GAGs exposed on EVs, and
(iii) Pharmacological inhibition of CCR8 with the small
molecule R243 inhibits EV uptake by GBM cells, resulting
in sensitisation of GBM cells to TMZ in vitro and in vivo.
Uptake of GBM EVs can induce cell growth in reci-
pient cells, confirming previous reports [9,10], but
seemed to have stronger phenotypic effects on TMZ
resistance in GBM, in particular in vivo. Tumour-
derived EVs have been implicated in resistance to
other types of therapy in various tumour types [15–
19]. By the use of the Cre-based colour switch model,
we demonstrated that transfer of active mRNA mole-
cules – such Cre recombinase – among GBM cells
occurs in vitro as well as in vivo, and that transferred
mRNA can be transcribed into functional molecules
once incorporated in recipient cells. Cre mRNA transfer
was observed both when we injected purified EVs into
the tumour and, more importantly, when donor cells
were allowed to naturally secrete Cre mRNA-loaded
EVs, implying that physiological levels of EVs reached
by tumour cells’ secretion are sufficient to target distant
cells and transcribe their cargo. We identified a set of
miRNAs in GBM EVs that have potential implications
in the process of TMZ resistance. Among the most
abundant miRNAs in GBM EVs, we observed a majority
of pro-tumoural, proliferation-inducing miRNAs, such
as miR-10b-5p, miR-92 and miR-21 (Supplementary
Figure 9(a,b)) [70–73]. More research is essential to
fully understand the mechanisms involved in the capa-
city of GBM EVs to induce TMZ resistance. TMZ is an
alkylating agent that transfers a methyl group to purine
bases in cellular DNA, causing incorrect pairing and
triggering the mismatch repair system (MMR), resulting
in cell cycle arrest and apoptosis in proliferating cells
[74–76]. Tumour cells become resistant to TMZ by
different mechanisms, including overexpression of
DNA repair mechanisms and multidrug efflux transpor-
ters such as P-gp, mutations in p53 and phosphatase and
tensin homolog (PTEN), and altered RNA expression
patterns [77–79]. The main inducer of TMZ resistance is
the DNA repair enzyme O6-methyl-guanidine methyl-
transferase (MGMT). The MGMT methylation status is
a better predictor of TMZ resistance than ‘stemness’ of
the glioblastoma cells [80]. MGMT counteracts TMZ
effects by direct removal of the O6-methyl group from
alkylated guanines [81]. Interestingly, it was reported
that GBM EVs from cell lines resistant to TMZ as well
as from treatment-refractory patients carry elevated
levels of MGMT mRNA, and that these levels are pre-
dictive for patient outcome [82]. We therefore do not
exclude that EV transfer of MGMT mRNA molecules
facilitates, at least partly, the resistance to TMZ observed
[60–63].
Here, we propose a model in which the chemokine
CCL18, a natural ligand of the CCR8 receptor, con-
nects glycans exposed on the EV membrane to the
CCR8 receptor expressed on GBM cells. Viruses and
EVs can have similar biophysical characteristics and
routes of biogenesis and uptake [29,30,83]. For
instance, it was reported that certain strains of HIV
can bind oligomers of CCL5 via glycans exposed on the
viral envelope, allowing viral attachment to the plasma
membrane of the target cell. CCL5 was also shown to
strongly induce uptake of (cellular, non-viral) EVs
from uninfected T lymphocytes [84]. Of note, it was
reported that enveloped viruses, such as HIV, can use
chemokine receptors as co-receptors, including CCR8
[51,85–87]. Moreover, natural ligands can compete
with these viruses for the co-receptors, inhibiting viral
uptake [88,89]. Exploring other viral co-receptors as
potential EV receptors could be of interest.
Myanishi et al. demonstrated that Tim1 and Tim4
can act as EV receptors by binding to phosphatidylser-
ine exposed on EVs. However, EV uptake by a certain
cell may not only depend on the presence of specific
cellular receptors, but in the case of bridging uptake
mechanisms, also on the availability of adaptor ligands,
either secreted by the recipient or donor cell, or by
other cells in the microenvironment. Here, we show
that CCL18 functions as bridging adaptor for GBM
EVs, and CCL18 expression has been identified as an
important prognostic factor in GBM [90]. Recently, it
was shown that EVs can also be decorated by autotaxin
resulting in binding to integrins expressed on cell sur-
faces [32]. Similarly, it was reported that heparan sul-
phates exposed on EVs can bind to fibronectin, serving
as a connecting molecule to heparan sulphates
expressed on cell membranes [34]. Christianson et al.
previously showed that heparan sulphate molecules
expressed on cell surfaces can function as EV receptors
on GBM cells [33], and others demonstrated that
heparin treatment reduces EV uptake by recipient
cells, including GBM cells [28,34,91–94]. We observed
that pretreatment of cells with heparin reduces EV
uptake to a lesser extent than pretreatment of EVs
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with heparin (data not shown), suggesting that both
mechanisms (direct heparin sulphate- and CCR8-
mediated endocytosis) can occur simultaneously. An
important consequence of the ‘connectokine’ model is
that it implies a complex level of regulation of EV
transfer, perhaps similarly as observed for decoration
of EVs with autotoxin [32] or fibronectin.
Interfering with selective EV uptake may be a promis-
ing approach to attack cancer cells, given the numerous
potential protumoural effects EVs can exert. Here, we
show that two CCR8 inhibitors, the peptide MC148 and
the small molecule inhibitor R243, were able to inhibit
EV uptake. Because the structure and the size of R243
allowed transport across the BBB, this compound was
selected for our in vivo experiments. R243, a small mole-
cule inhibitor of CCR8, inhibits EV uptake and counter-
acts EV-induced responses in recipient GBM cells in
vitro and in vivo. R243 did not only influence the inter-
action of EVs and the GBM8 cell line, but had similar
effects in two other GBM cell lines and in a melanoma
cell line, suggesting a general role of CCR8-EV interac-
tion, although the exact role of CCR8 expression on
other non-cancerous cells – remains to be investigated.
For instance, Th2 lymphocytes are known to express
high levels of CCR8 [50,95–97], which we were not
able to analyse in our nude mouse xenograft models
with primary human GBM stem-like brain tumours. In
addition, we do not exclude that other receptors can
function in the uptake of GBM EVs, and perhaps addi-
tional chemokine/chemokine receptor pairs play a role in
the tropism determination of EVs. Complex networks of
chemokine/chemokine receptor pairs are known to
induce tumour cell survival, angiogenesis, invasion as
well as recruitment to metastatic niches. These networks
act in both autocrine and paracrine fashion, establishing
virtual reciprocal dialogues between the tumour and its
environment. The CCR8 axis has been related to several
cancer progression-related processes in lymphoma,
urothelial and renal carcinomas, breast, and pancreatic
cancers [53,54,98–101]. Noteworthy, in melanoma,
where EV-mediated communication has been shown to
be key for metastasis [5,102], highly malignant cells
express elevated levels of CCR8 and migrate to the
lymph node in response to the secretion of the ligand
by lymphatic endothelial cells. Blocking of the CCR8 axis
resulted in strong reduction of metastatic transit through
the lymph node in xenograft models [55], suggestive of a
potential role of EV uptake via CCR8 during melanoma
metastasis.
In summary, we describe a mechanism of EV uptake
involving a chemokine receptor and its natural ligand
acting as a connecting adaptor. Inhibition of CCR8
decreased EV-induced phenotypes in GBM in vitro
and in vivo models, opening the door to new antic-
ancer approaches based on chemokine-receptor target-
ing of tumour EV crosstalk.
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